The collaboration with a reputable health organization like Hackensack Meridian Health could be seen as a positive step towards the development and regulatory approval of Compass Pathways' COMP360 psilocybin treatment. This partnership may increase investor confidence in the company's ability to bring the treatment to market, potentially leading to a short-term positive impact on the stock price.